Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX adjuvant chemotherapy for locally advanced gastric cancer
ChiCTR2000039356Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: 3-year disease-free survival rate. Started Nov 2020; status: recruiting.
02
Drugs
Rivoceraniboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000039356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039356.